Skip to content

Cleary Antitrust Watch

Cleary Gottlieb Steen & Hamilton LLP logo

Menu

HomeTopicsSub-MenuAbuseCartelsConsumer ProtectionForeign SubsidiesMarket Studies & InvestigationsMergers & AcquisitionsPolicy & ProcedurePrivate EnforcementState AidVertical AgreementsJurisdictionsSub-MenuEuropean UnionFranceGermanyItalySpainUnited KingdomUnited StatesIndustriesSub-MenuAerospace & DefenseAutomotive & MobilityBanking & Financial ServicesConsumer Goods & RetailEnergy, Chemicals & InfrastructureLeisure & HotelsLife Sciences & HealthcareLogistics & TransportationPublic ServicesReal Estate & ConstructionRenewable Energy, Sustainability & RecyclingSportsTechnology, Media & CommunicationsMultimediaSub-MenuPodcastsPublicationsWebinarsContact
View our LinkedIn Profile Follow us on Twitter Join Us on Facebook
Search

CMA Fines Advanz Pharma for Excessive and Unfair Prices in the Supply of Liothyronine Tablets

By Cleary Gottlieb on July 29, 2021

On 29 July 2021, the CMA announced that it had imposed a fine of £101 million on Advanz Pharma for abusing its dominant position by charging excessive and unfair prices for liothyronine tablets between 2009 and 2017.

Posted in Abuse, Life Sciences & Healthcare, United Kingdom
Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Related Posts
Antitrust-Review-Episode40-1200x628
Antitrust Review Episode 40: In Conversation With Marcus Bokkerink
March 18, 2025
Antitrust Review-Episode38-1200x628
Antitrust Review Episode 38: Current Developments in U.S., EU, and UK Competition Enforcement
February 20, 2025
mergers-2040435299-Color-1200x675
Learnings from Vodafone/Three
December 6, 2024

Stay Connected

Recent Posts

  • Antitrust Review Episode 45: In conversation with Jorge Padilla, Neil Dryden, Ethel Fonseca, Katie Curry & Chris Cook
  • Antitrust Review Episode 44: In conversation with Olivier Guersent
  • German Court Reaffirms That Transaction Value-Based Test Is Only a Backstop
  • Delivery Hero and Glovo Cartel EU Fine Delivers Warning About Antitrust Risks of Holding Minority Stake in a Rival
  • Antitrust Review Episode 43: In conversation with Cani Fernández

Follow Us

View our LinkedIn Profile Follow us on Twitter Join Us on Facebook

Archives

View our LinkedIn Profile Follow us on Twitter Join Us on Facebook
Privacy StatementDisclaimerTerms of Use & Legal Notices
  • About
  • Jurisdictions
  • Industries
  • Contact
  • European Union
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • United States
Copyright © 2025, Cleary Gottlieb Steen & Hamilton LLP. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo

WE VALUE YOUR PRIVACY

This site uses cookies and full details are set out in our Cookie Policy. Essential Cookies are always on; to accept Analytics Cookies, click "I agree to all cookies."

I agree to all cookiesReject